优势价格
快速发货
品质保证
技术支持
400-920-2911 sales@csnpharm.cn
Vasopressin Receptor
| 货号 | 产品名 | CAS号 | 信息 |
|---|---|---|---|
| CSN27225 | WAY 151932 | 220460-92-4 | WAY-151932 is a vasopressin V2-receptor agonist with IC50 of 80.3 nM and 778 nM in human-V2 binding and V1a binding assay. |
| CSN12057 | Terlipressin | 14636-12-5 | Terlipressin, an analog of vasopressin, acts as vasoconstrictor via V1 receptors on arteriolar smooth muscle cells and can reduce visceral blood flow. It is used to treat hypotension. |
| CSN20586 | SR49059 | 150375-75-0 | SR49059 is a potent and selective non-peptide vasopressin V1A receptor antagonist which is devoid of agonist activity. SR49059 displays high affinity and efficacy at both rat (Ki = 1.6 nM) and human (Ki = 1.1 - 6.3 nM) V1A receptors and potently antagonizes arginine vasopressin-induced effects in vitro (IC50 = 3.7 nM for inhibition of human platelet aggregation) and is orally active in vivo. |
| CSN21123 | OPC 21268 | 131631-89-5 | OPC-21268 is an antagonist of vasopressin V1 receptor with IC50 of 0.4 μM. |
| CSN12760 | Mozavaptan | 137975-06-5 | Mozavaptan is a competitive vasopressin receptor antagonist for both V1 and V2 receptors with IC50 of 1.2 μM and 14 nM, respectively. |
| CSN13437 | Conivaptan HCl | 168626-94-6 | Conivaptan HCl is an inhibitor of antidiuretic hormone or antagonist of vasopressin receptor. It can inhibit rat liver V1A receptor and kidney V2 receptor with Ki of 0.48 nM and 3.04 nM, respectively. |
| CSN10352 | Atosiban | 90779-69-4 | Atosiban is competitive antagonist of vasopressin and oxytocin receptors. It is a nonapeptide and the analogue of desamino-oxytocin. |
| CSN29535 | Atosiban acetate | 914453-95-5 | Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, atosiban suppresses oxytocin-mediated release of PGE and PGF from the decidua. In human pre-term labor, atosiban, at the recommended dosage, antagonizes uterine contractions and induces uterine quiescence. The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence. |
